Can Lorazepam (Ativan) Cause Urinary Retention?
Yes, lorazepam can cause urinary retention, though this is a rare adverse effect. The FDA drug label for Ativan explicitly lists urinary incontinence (not retention) in postmarketing reports, but one clinical trial documented a case of urinary retention that resolved without discontinuing the drug 1, 2.
Evidence from FDA Drug Label
The official Ativan prescribing information includes urinary incontinence among postmarketing adverse events 1. However, in a 1978 clinical trial of 68 patients treated with lorazepam for anxiety, one patient experienced urinary retention as a side effect, which resolved without requiring drug discontinuation 2.
Mechanism and Clinical Context
Benzodiazepines, including lorazepam, are recognized as medications that can impair micturition through:
- Smooth muscle relaxation effects on the detrusor muscle
- Central nervous system depression affecting bladder control mechanisms
- Potential anxiolytic effects that may paradoxically help in some cases 3
The evidence shows contradictory effects: while benzodiazepines are listed among drug classes associated with urinary retention 3, one case report actually used lorazepam successfully (combined with tamsulosin) to treat acute urinary retention in a remote setting, suggesting its smooth muscle relaxant properties may sometimes facilitate voiding 4.
Risk Factors to Consider
Elderly patients are at substantially higher risk for drug-induced urinary retention due to:
- Coexisting benign prostatic hyperplasia (BPH) in men
- Concurrent use of other medications with anticholinergic or urinary effects
- Age-related changes in drug metabolism 3
Lorazepam pharmacokinetics show a 20% decrease in clearance in elderly patients (60-84 years) compared to younger adults, potentially increasing exposure and side effects 1.
Clinical Trial Evidence
A randomized controlled trial specifically tested whether lorazepam could reduce postoperative urinary retention after gynecologic surgery. The study found no significant difference in time to void between lorazepam (3.1 ± 1.2 hours) and placebo (2.8 ± 2.0 hours) groups, suggesting lorazepam neither prevents nor significantly promotes urinary retention in this surgical context 5.
Practical Recommendations
Monitor for urinary retention in:
- Elderly male patients, especially those with known or suspected BPH
- Patients on multiple medications with anticholinergic properties
- Patients receiving higher doses or prolonged treatment
If urinary retention develops:
- Consider dose reduction rather than immediate discontinuation, as the single documented case resolved without stopping the drug 2
- Evaluate for other contributing medications or underlying urological conditions
- Catheterization may be necessary for acute symptomatic retention
Important Caveats
The incidence of lorazepam-induced urinary retention appears to be very low based on available evidence. The FDA label does not list urinary retention as a common or expected adverse effect. When urinary retention occurs in patients taking benzodiazepines, other contributing factors (polypharmacy, BPH, anticholinergic medications, opioids) are often present and may be the primary culprits 3, 6.